Clinical benefits of non‐taxane chemotherapies in unselected patients with symptomatic metastatic castration‐resistant prostate cancer after docetaxel: the GETUG‐P02 study. (January 2015)

• Record Type: Journal Article
• Authors: Joly, Florence; Delva, Remy; Mourey, Loïc; Sevin, Emmanuel; Bompas, Emmanuelle; Vedrine, Lionel; Ravaud, Alain; Eymard, Jean‐Christophe; Tubiana‐Mathieu, Nicole; Linassier, Claude; Houede, Nadine; Guillot, Aline; Ringensen, François; Cojocarasu, Oana; Valenza, Bruno; Leconte, Alexandra; Lheureux, Stéphanie; Clarisse, Bénédicte; Oudard, Stéphane
• Is Part Of: BJU international. Volume 115:Number 1(2015:Jan.)
• Page Start: 65
• Page End: 73
• Publication Date: 2015-01
• Subjects: Genitourinary organs -- Diseases -- Periodicals; Genitourinary organs -- Surgery -- Periodicals; Urology -- Periodicals; 616.6
• DOI: 10.1111/bju.12552
• Languages: English
• ISSNs: 1464-4096

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bju12552-sec-0001" sec-type="section"> <title>Objective</title> <p>To evaluate the overall benefits of non‐taxane chemotherapies in a non‐selected population including unfit patients presenting with symptoms and pain.</p> </sec> <sec id="bju12552-sec-0002" sec-type="section"> <title>Patients and Methods</title> <p>This randomized phase II study reports data from 92 patients (52% >70 years old; 40% with a performance score of 2) previously treated with taxane‐based chemotherapy, collected from 15 centres in France.</p> <p>Patients received i.v. mitoxantrone (MTX), oral vinorelbine, or oral etoposide, together with oral prednisone.</p> <p>Palliative benefit (pain response without progression of the disease), biological and tumoural responses, and toxicity profile as well as geriatric assessment (in elderly population) were analysed on an intention‐to‐treat basis.</p> </sec> <sec id="bju12552-sec-0003" sec-type="section"> <title>Results</title> <p>The palliative response rate was 17% for the whole population, and reached 29% when considering the MTX arm.</p> <p>Pain control was achieved in 40% of the patients. The median overall survival was 10.4 months, and was longer in palliative responders.</p> <p>Few grade 3–4 toxicities were observed.</p> <p>The subgroup analysis of elderly patients showed similar results regarding the number and dose intensity of treatments, efficacy and safety.</p> </sec> <sec id="bju12552-sec-0004" sec-type="section"> <title>Conclusion</title> <p>In a population including frail and/or elderly patients, who are poorly represented in most clinical studies, non‐taxane chemotherapy may remain a relevant option for metastatic prostate cancer having relapsed after a docetaxel‐based regimen.</p> <p>Although new treatment options are now approved, the decision‐making process should take into account their expected benefit/risk ratio based on the patient status.</p> </sec> </abstract>